Impact of gestrinone on the course of asymptomatic endometriosis.
- 31 January 1987
- Vol. 294 (6567), 272-274
- https://doi.org/10.1136/bmj.294.6567.272
Abstract
A new drug, gestrinone, was subjected to the first double blind, randomised placebo controlled trial of any treatment of endometriosis. The disease deteriorated in eight (47%) of the 17 patients prescribed placebo (95% confidence limits 23% and 71%) compared with none of the 18 patients prescribed gestrinone (p = 0.002). There was a difference in elimination of the endometriosis in the gestrinone group compared with placebo but this was not statistically significant (p = 0.057). There was a significant difference in improvement of the disease in the gestrinone group compared with placebo (p = 0.004), confirming that gestrinone is an effective treatment of endometriosis. Endometriosis deteriorates in at least 23% of patients; as it is impossible to predict in whom this will happen, treatment appears to be warranted in all cases.Keywords
This publication has 13 references indexed in Scilit:
- Population study of causes, treatment, and outcome of infertility.BMJ, 1985
- Effect of gestrinone in endometriosis tissue and endometriumFertility and Sterility, 1985
- Treatment of endometriosis with danazol: report of a 6-year prospective studyFertility and Sterility, 1985
- A comparative study of various dosages of danazol in the treatment of endometriosisBJOG: An International Journal of Obstetrics and Gynaecology, 1984
- Intranasal treatment with luteinising hormone releasing hormone agonist in women with endometriosis.BMJ, 1983
- Treatment of endometriosis with gestrinone (R-2323), a synthetic antiestrogen, antiprogesteroneAmerican Journal of Obstetrics and Gynecology, 1982
- ULTRASTRUCTURAL-CHANGES IN ENDOMETRIOTIC IMPLANTS DURING THE MENSTRUAL-CYCLE1981
- Action of a midcycle contraceptive (R 2323) on the human endometriumAmerican Journal of Obstetrics and Gynecology, 1976
- A new approach to estrogen-free contraception based on progesterone receptor blockage by mid-cycle administration of ethyl norgestrienone (R 2323)Contraception, 1974
- Conservative treatment and therapeutic test for endometriosis by androgensAmerican Journal of Obstetrics and Gynecology, 1947